ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer
ATR: targeting mechanical stress induced EMT and immune suppression in triple negative breast cancer
批准号:
10658429
负责人:
Zhenkun Lou
金额:
$36.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2028-07-31
关键词:
ATR geneBehaviorBiopsy SpecimenBreast Cancer cell lineCell CycleCell WallCellsCessation of lifeClinical TrialsComplexCytoskeletonDNA DamageDNA RepairDNA replication forkDataDeath RateDepositionDeubiquitinating EnzymeDeubiquitinationDiseaseDisease ProgressionDistant MetastasisEnrollmentEpithelial CellsExtracellular MatrixGenetically Engineered MouseGenome StabilityGoalsHealthImmune EvasionImmune System DiseasesImmune systemImmunologic SurveillanceImmunosuppressionImmunotherapeutic agentImmunotherapyInstitutionInvadedMalignant NeoplasmsMechanical StressMediatingMesenchymalModelingNeoplasm MetastasisNuclearNuclear TranslocationPathway interactionsPatientsPhenotypePlayProcessPrognosisProgression-Free SurvivalsPropertyProteinsRegulationResistanceRoleSamplingSignal PathwaySocietiesStimulusTestingTherapeuticTissuesTumor Cell InvasionTumor ImmunityTumor Suppressor ProteinsUnited StatesVariantXenograft procedureaggressive breast canceranti-PD-1anti-PD1 therapyataxia telangiectasia mutated proteinbeta cateninbreast cancer diagnosisbreast cancer progressioncancer celldisorder subtypeepithelial to mesenchymal transitionfightingin vivoinhibitorinsightmalignant breast neoplasmmechanical stimulusnovel strategiesperipheral bloodprogramsprotein expressionresponseresponse biomarkerstem-like celltherapy resistanttriple-negative invasive breast carcinomatumortumor progressionubiquitin isopeptidase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT DESCRIPTION/ABSTRACT
Therapeutically resistant triple negative breast cancer (TNBC) is characterized by mesenchymal features that
facilitate immune evasion and disease progression, resulting in high rates of death from the disease. New
strategies targeting the mesenchymal phenotype to overcome therapeutic resistance are needed. Interactions
between the cytoskeleton of cancer cells and the surrounding extracellular matrix play important roles in initiating
local invasion and metastasis. The resulting mechanical stimuli activate signaling pathways which promote the
transition of non-motile polarized epithelial cells to cells with mesenchymal properties that are able to invade
surrounding tissues and evade immune surveillance, a process termed epithelial to mesenchymal transition
(EMT). Fibrotic stiffening of the non-cellular stroma resulting from extracellular matrix deposition is a common
feature of TNBC and other malignancies that is associated with therapeutic resistance and poor prognosis. How
mechanical stress promotes EMT and cancer progression has not been elucidated.
Ataxia Telangiectasia Mutated and Rad-3 Related (ATR) is best known as a regulator of the DNA damage
response in replicating cells. In our preliminary data, we have found that high ATR protein expression is
associated with reduced progression-free survival in TNBC. We discovered that ATR is post-translationally
upregulated by a deubiquitinating enzyme, USP21, in response to mechanical stress, and that ATR regulates
the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex to promote β-catenin nuclear translocation and
mechanical stress-induced EMT. This new role for ATR in mechanical stress and EMT is independent of ATR’s
established function in regulating the DNA damage response. In a clinical trial of anti-PD-1 immunotherapy for
advanced TNBC, high ATR levels in biopsy specimens was correlated with EMT and reduced responsiveness.
ATR inhibition could promote mesenchymal to epithelial transition and anti-tumor immunity in vivo. We
hypothesize that ATR regulates the LINC complex following mechanical stress to promote β-catenin mediated
EMT, immune evasion, and TNBC progression. We will test this hypothesis through three specific aims. Aim 1
will examine the impact of mechanical stress on ATR deubiquitination and the LINC complex; Aim 2 will evaluate
how ATR influences β-catenin pathway activation and EMT; Aim 3 will investigate the role of ATR-SUN2 in
stiffness and EMT associated immune evasion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
-
批准号:10305524
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2021
-
负责人:Zhenkun Lou
-
依托单位:
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
-
批准号:10415197
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2021
-
负责人:Zhenkun Lou
-
依托单位:
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment
-
批准号:10610944
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2021
-
负责人:Zhenkun Lou
-
依托单位:
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
-
批准号:10553119
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2020
-
负责人:Zhenkun Lou
-
依托单位:
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
-
批准号:10361225
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2020
-
负责人:Zhenkun Lou
-
依托单位:
The role of nuclear PD-L1 in breast tumor cell division, progression and therapy response
-
批准号:9897018
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2020
-
负责人:Zhenkun Lou
-
依托单位:
Regulation of Necroptosis and inflammation
-
批准号:10534748
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2019
-
负责人:Zhenkun Lou
-
依托单位:
Regulation of Necroptosis and inflammation
-
批准号:10316176
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2019
-
负责人:Zhenkun Lou
-
依托单位:
UFM1 signaling in DNA damage response and cancer therapy
-
批准号:10304188
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2017
-
负责人:Zhenkun Lou
-
依托单位:
UFM1 signaling in DNA damage response and cancer therapy
-
批准号:10057359
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2017
-
负责人:Zhenkun Lou
-
依托单位:
UFM1 signaling in DNA damage response and cancer therapy
-
批准号:9406523
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2017
-
负责人:Zhenkun Lou
-
依托单位:
Regulation of homologous recombination and cancer cell response to chemoradiotherapy
-
批准号:9055788
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2015
-
负责人:Zhenkun Lou
-
依托单位:
The Role of WSB1 in Tumorigenesis
-
批准号:9125795
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2014
-
负责人:Zhenkun Lou
-
依托单位:
The Role of WSB1 in Tumorigenesis
-
批准号:9330110
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2014
-
负责人:Zhenkun Lou
-
依托单位:
The Role of WSB1 in Tumorigenesis
-
批准号:8786949
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2014
-
负责人:Zhenkun Lou
-
依托单位:
Regultion of p53 Deubiquitination
-
批准号:8206756
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2011
-
负责人:Zhenkun Lou
-
依托单位:
Regultion of p53 Deubiquitination
-
批准号:8775203
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2011
-
负责人:Zhenkun Lou
-
依托单位:
Regultion of p53 Deubiquitination
-
批准号:8588904
-
项目类别:
-
资助金额:$31.74万
-
财政年份:2011
-
负责人:Zhenkun Lou
-
依托单位:
Regultion of p53 Deubiquitination
-
批准号:8408814
-
项目类别:
-
资助金额:$30.76万
-
财政年份:2011
-
负责人:Zhenkun Lou
-
依托单位:
Regultion of p53 Deubiquitination
-
批准号:8037330
-
项目类别:
-
资助金额:$32.72万
-
财政年份:2011
-
负责人:Zhenkun Lou
-
依托单位:
国内基金
海外基金
greenwashing behavior in China:Basedon an integrated view of reconfiguration of environmental authority and decoupling logic
-
批准号:--
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:YU BYUNGJUN
-
依托单位:
Incentive and governance schenism study of corporate green washing behavior in China: Based on an integiated view of econfiguration of environmental authority and decoupling logic
-
批准号:--
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:YU BYUNGJUN
-
依托单位: